Walker Chloe J, Flanagan Kelly E, Pathoulas James T, Pupo Wiss Isabel, Senna Maryanne M
Department of Dermatology, Harvard Medical School-Massachusetts General Hospital, Boston, Massachusetts, USA.
Skin Appendage Disord. 2021 Aug;7(5):408-412. doi: 10.1159/000516300. Epub 2021 Jun 9.
Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ.
Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis.
Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.
托珠单抗(TCZ)是一种靶向白细胞介素-6(IL-6)信号传导的重组人源化抗人单克隆抗体,常用于自身免疫性疾病的治疗。很少有报告显示使用托珠单抗的患者毛发有生长变化。
在此,我们回顾文献并报告一名21岁患有进行性斑秃(AA)的女性,她在因并发后葡萄膜炎而使用托珠单抗治疗期间斑秃情况有所改善。
我们的病例表明托珠单抗具有破坏斑秃中涉及的IL-6信号传导的潜在能力,从而导致脱发和毛发再生。